AstraZeneca PLC ADRhedged
AZNH
New York Stock Exchange Arca- -
USD
- -
- -
- -
- -
(- -)
Recent
price
- -
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- AstraZeneca PLC ADRhedged ETF (AZNH) is an exchange-traded fund that provides U.S. investors with exposure to the American Depositary Receipts (ADRs) of AstraZeneca PLC, a UK-listed biopharmaceutical company, while incorporating a currency hedge to mitigate volatility between the British pound and the U.S. dollar. The underlying AstraZeneca PLC, formed in 1999 through the merger of Sweden's Astra AB (founded 1913) and the UK's Zeneca Group PLC, is headquartered in Cambridge, United Kingdom, and operates globally with medicine sales in over 130 countries; key subsidiaries include MedImmune and the recently integrated Fusion Pharmaceuticals. AstraZeneca focuses on three main therapy areas—Oncology, BioPharmaceuticals, and Rare Disease—developing, manufacturing and commercializing prescription medicines such as Tagrisso and Enhertu (oncology), Farxiga (cardiovascular, renal and metabolism), Imfinzi (oncology and bioimmunotherapy), Lynparza (oncology), Symbicort and Breztri (respiratory and immunology), as well as vaccines and immune therapies; its pipeline comprises nearly 200 programs, including 18 late-stage new molecular entities targeting high-unmet needs in cancer, metabolic disorders and rare conditions. Recent developments include a $50 billion U.S. investment commitment by 2030 for manufacturing expansions in states including Virginia, Maryland, Massachusetts, California, Indiana and Texas; $2 billion additional biologics manufacturing push in Frederick, Maryland; the May 2025 completion of the up-to-$1 billion acquisition of EsoBiotec to bolster in vivo cell therapies for oncology and immune diseases; the November 2025 $170 million acquisition of obesity-focused SixPeaks Bio; a up-to-$555 million licensing deal in October 2025 with Algen Biotechnologies for AI-driven gene therapies; and a June 2025 strategic research partnership with CSPC Pharmaceuticals worth up to $1.73 billion for chronic disease candidates, alongside 16 Phase III readouts and 31 regulatory approvals year-to-date in 2025.